Development and prospective validation of a spatial dose pattern based model predicting acute pulmonary toxicity in patients treated with volumetric arc-therapy for locally advanced lung cancer

被引:10
作者
Bourbonne, Vincent [1 ,2 ]
Lucia, Francois [1 ,2 ]
Jaouen, Vincent [2 ,3 ]
Bert, Julien [2 ]
Rehn, Martin [1 ]
Pradier, Olivier [1 ,2 ]
Visvikis, Dimitris [2 ]
Schick, Ulrike [1 ,2 ]
机构
[1] Univ Hosp, Dept Radiat Oncol, Brest, France
[2] Univ Brest, LaTIM UMR 1101 INSERM, Brest, France
[3] Inst Mines Telecom Atlantique, Brest, France
关键词
radiation pneumonitis; lung cancer; prediction; cluster of voxel; INTENSITY-MODULATED RADIOTHERAPY; FUNCTIONAL AVOIDANCE; REGIONAL VENTILATION; RADIATION; PNEUMONITIS; PERFUSION; IMPACT; IMRT;
D O I
10.1016/j.radonc.2021.09.008
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction: (Chemo)-radiotherapy is the standard treatment for patients with locally advanced lung cancer (LALC) not accessible to surgery. Despite strict application of dose constraints, acute toxicities such as acute pulmonary toxicity (APT) remain frequent, and may impact treatment's compliance and patients' quality of life. Previously, on a population treated with intensity-modulated photon therapy or passive scattering proton therapy, spatial dose patterns associated with APT were identified in the lower lungs, especially in the posterior right lung. In the present study, we aim to define these spatial dose patterns on a retrospective cohort treated by volumetric-arctherapy (VMAT) and to validate our findings prospectively. Methods: For the training cohort, we retrospectively included all patients treated in our institution by VMAT for a LALC between 2015 and 2018. APT was scored according to the CTCAE v4.0 scale. All dose maps were registered to a thorax phantom using a segmentation-based elastic registration. Voxelbased analysis of local dose differences was performed with a non-parametric permutation test accounting for n = 10.000 permutations, producing a 3-dimensional significance maps on which clusters of voxels that exhibited significant dose differences (p < 0.05) between the two toxicity groups (APT > grade 2 vs APT < grade 2) were identified. A prediction model (Pmap-Model) was then built using a neural network approach and then applied to an observational prospective cohort for validation. The model was evaluated using the Area under the curve (AUC) and the balanced accuracy (Bacc: mean of the sensitivity and specificity). Results: 165 and 42 patients were included in the training and validation cohorts, with respective APT rates of 22.4% and 19.1%. In the training cohort, a cluster of voxels (Pmap-region) was identified in the posterior right lung. In the training cohort, the Pmap-Model combining 11 features among which the mean dose to the Pmap-region resulted in an AUC of 0.99 and a Bacc of 99.2 using an 8% probability threshold. Using the same voxel cluster on the validation cohort, the Pmap-model resulted in an AUC of 0.81 and a Bacc of 82.0. Conclusion: Our APT-prediction model was successfully validated in a prospective cohort treated by VMAT. Regional radiosensitivity should be considered in usual lung dose constraints, opening the possibility of easily implementable adaptive dosimetry planning. (c) 2021 Elsevier B.V. All rights reserved. Radiotherapy and Oncology 164 (2021) 43-49
引用
收藏
页码:43 / 49
页数:7
相关论文
共 29 条
  • [1] Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
    Antonia, S. J.
    Villegas, A.
    Daniel, D.
    Vicente, D.
    Murakami, S.
    Hui, R.
    Kurata, T.
    Chiappori, A.
    Lee, K. H.
    de Wit, M.
    Cho, B. C.
    Bourhaba, M.
    Quantin, X.
    Tokito, T.
    Mekhail, T.
    Planchard, D.
    Kim, Y. -C.
    Karapetis, C. S.
    Hiret, S.
    Ostoros, G.
    Kubota, K.
    Gray, J. E.
    Paz-Ares, L.
    Carpeno, J. de Castro
    Faivre-Finn, C.
    Reck, M.
    Vansteenkiste, J.
    Spigel, D. R.
    Wadsworth, C.
    Melillo, G.
    Taboada, M.
    Dennis, P. A.
    Ozguroglu, M.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (24) : 2342 - 2350
  • [2] Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer
    Antonia, S. J.
    Villegas, A.
    Daniel, D.
    Vicente, D.
    Murakami, S.
    Hui, R.
    Yokoi, T.
    Chiappori, A.
    Lee, K. H.
    de Wit, M.
    Cho, B. C.
    Bourhaba, M.
    Quantin, X.
    Tokito, T.
    Mekhail, T.
    Planchard, D.
    Kim, Y. -C.
    Karapetis, C. S.
    Hiret, S.
    Ostoros, G.
    Kubota, K.
    Gray, J. E.
    Paz-Ares, L.
    de Castro Carpeno, J.
    Wadsworth, C.
    Melillo, G.
    Jiang, H.
    Huang, Y.
    Dennis, P. A.
    Ozguroglu, M.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (20) : 1919 - 1929
  • [3] Radiomics analysis of 3D dose distributions to predict toxicity of radiotherapy for lung cancer
    Bourbonne, V.
    Da-ano, R.
    Jaouen, V.
    Lucia, F.
    Dissaux, G.
    Bert, J.
    Pradier, O.
    Visvikis, D.
    Hatt, M.
    Schick, U.
    [J]. RADIOTHERAPY AND ONCOLOGY, 2021, 155 : 144 - 150
  • [4] Single-arm prospective interventional study assessing feasibility of using gallium-68 ventilation and perfusion PET/CT to avoid functional lung in patients with stage III non-small cell lung cancer
    Bucknell, Nicholas
    Hardcastle, Nicholas
    Jackson, Price
    Hofman, Michael
    Callahan, Jason
    Eu, Peter
    Iravani, Amir
    Lawrence, Rhonda
    Martin, Olga
    Bressel, Mathias
    Woon, Beverley
    Blyth, Benjamin
    MacManus, Michael
    Byrne, Keelan
    Steinfort, Daniel
    Kron, Tomas
    Hanna, Gerard
    Ball, David
    Siva, Shankar
    [J]. BMJ OPEN, 2020, 10 (12):
  • [5] Comparison of inverse-planned three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for non-small-cell lung cancer
    Christian, Judith A.
    Bedford, James L.
    Webb, Steve
    Brada, Michael
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2007, 67 (03): : 735 - 741
  • [6] Clark T, 2019, CURR PROBL DIAGN RAD
  • [7] NCCN Guidelines® Insights: Non-Small Cell Lung Cancer, Version 4.2016 Featured Updates to the NCCN Guidelines
    Ettinger, David S.
    Wood, Douglas E.
    Akerley, Wallace
    Bazhenova, Lyudmila A.
    Borghaei, Hossein
    Camidge, David Ross
    Cheney, Richard T.
    Chirieac, Lucian R.
    D'Amico, Thomas A.
    Dilling, Thomas J.
    Dobelbower, M. Chris
    Govindan, Ramaswamy
    Hennon, Mark
    Horn, Leora
    Jahan, Thierry M.
    Komaki, Ritsuko
    Lackner, Rudy P.
    Lanuti, Michael
    Lilenbaum, Rogerio
    Lin, Jules
    Loo, Billy W., Jr.
    Martins, Renato
    Otterson, Gregory A.
    Patel, Jyoti D.
    Pisters, Katherine M.
    Reckamp, Karen
    Riely, Gregory J.
    Schild, Steven E.
    Shapiro, Theresa A.
    Sharma, Neelesh
    Stevenson, James
    Swanson, Scott J.
    Tauer, Kurt
    Yang, Stephen C.
    Gregory, Kristina
    Hughes, Miranda
    [J]. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2016, 14 (03): : 255 - 264
  • [8] Potential for reduced toxicity and dose escalation in the treatment of inoperable non-small-cell lung cancer: A comparison of intensity-modulated radiation therapy (IMRT), 3D conformal radiation, and elective nodal irradiation
    Grills, IS
    Yan, D
    Martinez, AA
    Vicini, FA
    Wong, JW
    Kestin, LL
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2003, 57 (03): : 875 - 890
  • [9] Regional ventilation and distribution of emphysema -: a quantitative comparison
    Johansson, Å
    Vikgren, J
    Moonen, M
    Tylén, U
    Bake, B
    [J]. CLINICAL PHYSIOLOGY AND FUNCTIONAL IMAGING, 2004, 24 (01) : 58 - 64
  • [10] New dose constraint reduces radiation-induced fatal pneumonitis in locally advanced non-small cell lung cancer patients treated with intensity-modulated radiotherapy
    Khalil, Azza A.
    Hoffmann, Lone
    Moeller, Ditte S.
    Farr, Katherina P.
    Knap, Marianne M.
    [J]. ACTA ONCOLOGICA, 2015, 54 (09) : 1343 - 1349